Grant: Project Grant
University of Toronto
$650,250.00
A systematic strategy to develop inhibitors of protein-protein interactions as potential therapeutics
FY 2016-17
Summary
The discovery of new drug targets is of paramount importance for the future of cancer therapy. Moreover, it is crucial to validate such target candidates and offer lead inhibitor molecules for them. Our project achieves both of these objectives and is widely applicable. It will hence lead to a great number of new drug targets for different cancer types (first focusing on pancreas cancer) as well as candidate molecules. These leads can directly be tested in vivo using established mouse models and then further optimized. In summary, our approach will be a great step forward in developing a variety of new cancer treatments and we expect it to become established as a general method for cancer researchers.
Department
Program
Project Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
357149
Name
Kim Philip M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
A systematic strategy to develop inhibitors of protein-protein interactions as potential therapeutics
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$650,250
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Computational Design; Inhibitor Design; Lentiviral Screen; Peptide Library; Peptide Motif; Protein Protein Interaction
Abstract
The discovery of new drug targets is of paramount importance for the future of cancer therapy. Moreover, it is crucial to validate such target candidates and offer lead inhibitor molecules for them. Our project achieves both of these objectives and is widely applicable. It will hence lead to a great number of new drug targets for different cancer types (first focusing on pancreas cancer) as well as candidate molecules. These leads can directly be tested in vivo using established mouse models and then further optimized. In summary, our approach will be a great step forward in developing a variety of new cancer treatments and we expect it to become established as a general method for cancer researchers.
Competitiondate
201610
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Kim, Philip M
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $650,250~ $0~
